Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: NOVARTIS FARMA
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 5 ans
An open-label, multicenter, efficacy and safety study of 4-month canakinumab treatment with 6-month follow-up in patients with active recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS)
To assess if canakinumab induces complete or almost complete response in patients with active TRAPS at Day 15 (defined as 15 days after the first dose).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 5 ans
A randomized, double-blind, active-controlled, multicenter study to compare the effect of 24 weeks treatment with a fixed dose combination therapy of vildagliptin/metformin to individual monotherapies in drug na ve patients with type 2 diabetes
To demonstrate the efficacy of initial fixed combination treatment with vildagliptin and metformin in drug na ve patients with T2DM by testing the hypotheses that the HbA1c reduction with fixed combin...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 5 ans
A 18-month, open-label, rater-blinded, randomized, multi-center, active-controlled, parallel-group pilot study to assess efficacy and safety of fingolimod (Gilenya) in comparison to interferon beta-1b in treating the cognitive symptoms associated to relapsing-remitting multiple sclerosis and to assess possible relationship of these effects to regional brain atrophy
The primary objective of this pilot study is to evaluate, by means of a specific cognitive test battery (Brief Repeatable Battery and Delis-Kaplan Executive Function System scale), the slowing/reduct...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 5 ans
An extension to a phase II study to determine the efficacy and the safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha estensione dello uno studio di fase II per determinare l`efficacia e la sicurezza di STI 571 in pazienti con LMC refrattari o intolleranti alla terapia con interferone-alfa
To decrease the frequency of bone marrow evaluations to once a year from once every 6 months for all patients who have achieved a complete cytogenetic response. This study objective has been met as ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 5 ans
A phase II, 12-month, double-blind, placebo-controlled, dose-finding, multicenter study to evaluate the safety, tolerability, and disease modifying efficacy of daily oral AAE581 (10, 25 and 50 mg tablets) in patients with painful knee osteoarthritis, Kellgren-Lawrence grade 3 by X-ray
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 5 ans
A study to investigate whether LJM716 in combination with cetuximab is safe and has beneficial effects in patients with advanced head and neck cancer who progressed on prior therapy
Phase Ib: To determine RP2D and estimate MTD of LJM716 in combination with cetuximab in patients with RM HNSCC Phase II: To access the anti-tumor activity of LJM716-cetuximab combination in cetuxima...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 5 ans
A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy
The primary objective of the study is to evaluate the change in patient-reported treatment satisfaction after 6 months of treatment with fingolimod 0.5mg/day vs. DMT standard of care, using the global...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 5 ans
A Six-month, Multicenter, Randomized, Open-label Study of the Safety, Tolerability and Efficacy of Two Neoral Doses in addition to Certican 61668; and Steroids in de novo Heart Transplant Recipients
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 5 ans
To evaluate the impact of early vs delayed introduction of everolimus on wound healing in patients newly transplanted kidney Valutazione dell'impatto dell'introduzione precoce di everolimus rispetto a quella ritardata sulla guarigione della ferita in pazienti appena trapiantati di rene
The primary objective of the study is to compare the proportion of patients without wound complications related to initial transplant surgery (i.e. lymphorrea, fluid collections, wound dehiscence, wou...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 5 ans
A phase Ib, multi-center, open-label, dose-escalation study of oral LBH589 when administered in combination with oral lenalidomide & dexamethasone in adult patients with multiple myeloma Studio multicentrico, di fase Ib in aperto, di incremento della dose di LBH589 somministrato per via orale in associazione a lenalidomide e desametasone per via orale in pazienti adulti con mieloma multiplo
To determine the MTD of LBH589 when used in combination with a fixed dose of lenalidomide & dexamethasone. Determinare la MTD di LBH589 somministrato per via orale in associazione a una dose fi...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
2
3
4
5
6
7
8
9
Next